---
title: "JXPCB released its first-quarter performance, with a net loss attributable to the parent company of 4.8547 million yuan, an expanded loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237560807.md"
description: "According to the Zhitong Finance APP, JXPCB released its first-quarter report for 2025, with the company's operating revenue in the first quarter reaching 124 million yuan, a year-on-year increase of 21.42%; the net loss attributable to shareholders of the listed company was 4.8547 million yuan, with losses widening; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 5.3736 million yuan, with losses widening; the basic loss per share was 0.04 yuan/share"
datetime: "2025-04-25T10:50:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237560807.md)
  - [en](https://longbridge.com/en/news/237560807.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237560807.md)
---

# JXPCB released its first-quarter performance, with a net loss attributable to the parent company of 4.8547 million yuan, an expanded loss

According to the Zhitong Finance APP, JXPCB (688655.SH) released its first-quarter report for 2025, reporting an operating income of 124 million yuan in the first quarter, a year-on-year increase of 21.42%; the net loss attributable to shareholders of the listed company was 4.8547 million yuan, with losses widening; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 5.3736 million yuan, with losses widening; the basic loss per share was 0.04 yuan/share

### Related Stocks

- [688655.CN](https://longbridge.com/en/quote/688655.CN.md)

## Related News & Research

- [Klick Health’s ‘18 Months’ Continues to Strike Gold With 29 Wins Alone During Creative Week](https://longbridge.com/en/news/287244265.md)
- [Orkla (OB:ORK) Margin Improvement Challenges Cautious Earnings Narratives Heading Into Q1 2026](https://longbridge.com/en/news/287134604.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [BRIEF-Mexico's Fibra Next Extends, Raises Public Offer For Fibra Macquarie](https://longbridge.com/en/news/287128862.md)
- [Innovaccer Acquires CaduceusHealth to Make Revenue Cycle Autonomous](https://longbridge.com/en/news/287202119.md)